GSK-3β inhibitor 14
GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak GSK-3β inhibitor (IC50 >100 μM) [1].
Product Specifications
CAS Number
863004-48-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
GSK-3
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/gsk-3β-inhibitor-14.html
Purity
99.92
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1CC(C)SC2=CC=CC=C2N1CC3=CC=CC=C3
Molecular Formula
C17H17NOS
Molecular Weight
283.39
Precautions
H302, H315, H319
References & Citations
[1]Zhang P, et al. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β) . Eur J Med Chem. 2013 Mar;61:95-103.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680676-500 1x 500 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400158-100 1x 100 µL
Cytokeratin 17 (E3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882216-500 1x 500 µL
CD50 / ICAM3 (CG106), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC741541-500 1x 500 µL
Calnexin (Endoplasmic Reticulum Marker) (CANX/1541), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details